Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Infinium Pharmachem's EBIT per Share for the
six
months ended in Mar. 2026 was ₹6.90.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹13.24.
During the past 12 months, the average EBIT per Share Growth Rate of Infinium Pharmachem was 31.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 3.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 25.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Infinium Pharmachem's EBIT per Share or its related term are showing as below:
NSE:INFINIUM'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 3.4 Med: 39.2 Max: 95.9
Current: 3.4
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Infinium Pharmachem was 95.90% per year. The lowest was 3.40% per year. And the median was 39.20% per year.
NSE:INFINIUM's 3-Year EBIT Growth Rate is ranked better than 56.39% of 1337
companies
in the Chemicals industry
Industry Median: -1.1
vs NSE:INFINIUM: 3.40
Infinium Pharmachem (NSE:INFINIUM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Infinium Pharmachem EBIT per Share Related Terms
Infinium Pharmachem EBIT per Share Historical Data
* Premium members only.
The historical data trend for Infinium Pharmachem's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹13.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infinium Pharmachem (NSE:INFINIUM) has a EBIT per Share of ₹13.24 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Infinium Pharmachem and its competitors. According to the industry distribution chart, Infinium Pharmachem ranks #583 out of 1337 companies in the Chemicals industry, placing it in the top 43.6%.
Is Infinium Pharmachem's EBIT per Share too high?
Infinium Pharmachem's current EBIT per Share is ₹13.24. Based on the distribution chart, Infinium Pharmachem ranks #583 out of 1337 companies in the Chemicals industry, which is above the industry midpoint. Overall, Infinium Pharmachem has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Infinium Pharmachem's EBIT per Share compare to DOW?
According to the Chemicals industry distribution chart, Infinium Pharmachem ranks #583 out of 1337 companies for EBIT per Share. This puts Infinium Pharmachem in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Chemicals company?
A good EBIT per Share depends on the Chemicals industry context. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Infinium Pharmachem and its competitors. Infinium Pharmachem's current EBIT per Share is ₹13.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinium Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Infinium Pharmachem (NSE:INFINIUM) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹306.60, compared to a current price of ₹206.05 — trading 32.8% below its estimated fair value. The current EBIT per Share is ₹13.24. Infinium Pharmachem's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Infinium Pharmachem (NSE:INFINIUM), the current EBIT per Share is ₹13.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Infinium Pharmachem (NSE:INFINIUM) Overvalued in 2026?
Based on GuruFocus' analysis, Infinium Pharmachem stock appears to be undervalued.
The current stock price of ₹206.05 is trading 32.8% below its estimated GF Value™ of ₹306.60.
GuruFocus considers Infinium Pharmachem to be Significantly Undervalued.
Key valuation signals for NSE:INFINIUM:
EBIT per Share: ₹13.24
GF Value™: ₹306.60 vs. price of ₹206.05 (32.8% below fair value)
No single metric tells the full story. See the NSE:INFINIUM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Infinium Pharmachem Ltd is engaged in the business of manufacturing and supplying Iodine, Iodine Derivatives and Active Pharmaceutical Ingredients (APIs). It provides fully integrated customized services from R & D to Commercial scale manufacturing and packaging for its products to the Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals and various other chemicals Industries.
86GF Score
Get the complete analysis for NSE:INFINIUM
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFINIUM has been successfully added to your 
